Eledon Pharmaceuticals Inc expected to post a loss of 60 cents a share - Earnings Preview

Eledon Pharmaceuticals

10/05/2023 03:04

* Eledon Pharmaceuticals Inc  ELDN.OQ   ELDN.O  is expected
to show no change in quarterly revenue when it reports 
results on May 11. 
    * 
    * ​Refinitiv's mean analyst estimate for Eledon
Pharmaceuticals
Inc is for a loss of 60 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 14.3%
in the last three months. ​
    * Wall Street's median 12-month price target for Eledon
Pharmaceuticals Inc is $12​, above​ its last closing price
of $2.75. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.78       -0.70      -0.69     Beat    1.6
 Sep. 30 2022  -0.68       -0.68      -0.73     Missed  -7.4
 Jun. 30 2022  -0.70       -0.70      -0.65     Beat    7.7​
 Mar. 31 2022  -0.67       -0.68      -0.69     Missed  -1.8
 ​​Dec.                    -0.75      -0.59     Beat    21.3
 31 2021                                                
 Sep. 30 2021  -0.63       -0.65      -0.66     Missed  -2.2​
 Jun. 30 2021  -0.58       -0.57      -0.50     Beat    11.9
 Mar. 31 2021  -0.34       -0.32      -0.57     Missed  -78.1
 This summary was machine generated May 10 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated